Miinalainen IJ: Difference between revisions

From Bioblast
Β 
(11 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{Person
{{Person
|firstname=PhD. Ikka
|lastname=Miinalainen
|lastname=Miinalainen
|address=NICB
|firstname=Ilkka
Β 
|title=Ph.D.
Centre for Bioanalytical Sciences (CBAS)
|institution=Biocenter Oulu Electron Microscopy Core Facility
Β 
University of Oulu
Dublin City University
|address=Aapistie 5A
Β 
|area code=90220
Glasnevin, Dublin 9, Ireland
|city=Oulu
|country=Finland
|weblink=[http://www.oulu.fi/biocenter/em Biocenter Oulo]
}}
}}
{{Labelingperson}}
== Participated at==
::::* [[IOC47|IOC47 Schroecken AT]]

Latest revision as of 16:30, 12 February 2018

Name Miinalainen Ilkka, Ph.D.
Institution Biocenter Oulu Electron Microscopy Core Facility

University of Oulu

Address Aapistie 5A, 90220
City Oulu
State/Province
Country Finland
Email [email protected]
Weblink Biocenter Oulo
O2k-Network Lab IE Dublin Miinalainen I


Labels:



Publications

 PublishedReference
Raesaenen 2016 Proc Natl Acad Sci U S A2016RΓ€sΓ€nen M, Degerman J, Nissinen TA, Miinalainen I, KerkelΓ€ R, Siltanen A, Backman JT, Mervaala E, Hulmi JJ, KivelΓ€ R, Alitalo K (2016) VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection. Proc Natl Acad Sci U S A 113:13144-49.

Abstracts

Add abstract

Participated at

Cookies help us deliver our services. By using our services, you agree to our use of cookies.